ScholarIQanswers from OpenAlex & ORCID
Jennifer J. Knox
ResearcherPublications, citations & collaboration network
Jennifer J. Knox is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jennifer J. Knox have?
ScholarIQindexed works
Jennifer J. Knox has 832 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jennifer J. Knox have?
ScholarIQcitation count
Jennifer J. Knox has 36,028 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jennifer J. Knox?
ScholarIQh-index
Jennifer J. Knox has an h-index of 81 in OpenAlex.
What is the i10-index of Jennifer J. Knox?
ScholarIQi10-index
Jennifer J. Knox has an i10-index of 262 in OpenAlex.
What is the ORCID of Jennifer J. Knox?
ScholarIQorcid
The ORCID for Jennifer J. Knox is on the source record.
What is the OpenAlex record for Jennifer J. Knox?
ScholarIQopenalex
The OpenAlex for Jennifer J. Knox is on the source record.
What are the most-cited papers on Jennifer J. Knox?
ScholarIQmost cited works
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, Chakshu Sahi, Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Abby B. Siegel, E. Cohen, Allyson J. Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul J. Christos, Madhu Mazumdar, E Popa, Robert S. Brown, Shahin Rafii, Jonathan D. Schwartz
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yañez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaoming Chen, Dong Yan, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean–Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer, Carlos H. Barrios, Tae Min Kim, S. Falcon, Thomas M. Cosgriff, W G Harker, Vichien Srimuninnimit, Ken Pittman, Roberto Sabbatini, Sun Young Rha, Thomas W. Flaig, Ray D. Page, Sevil Bavbek, J. Thaddeus Beck, Poulam M. Patel, F.Y. Cheung, Sunil Kumar Yadav, Edward Schiff, Xufang Wang, Julie Niolat, Dalila Sellami, Oezlem Anak, Jennifer J. Knox